Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SPEVIGO safely and effectively. See full prescribing information for SPEVIGO. SPEVIGO® (spesolimab-sbzo) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.
- generic_name
- spesolimab
- product_names
- spesolimab
- ndc
- 50222-362, 50222-361, 50222-360, 50222-362-12, 50222-362-01, 50222-362-02, 50222-361-11, 50222-361-02, 50222-360-72
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en